

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-12 (canceled)

Claim 13 (Currently Amended): A method of prevention and [[or]] treatment of ~~an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma, when needed,~~ which comprises ~~administering, by inhalation, to a patient~~ instructing a patient to inhale an effective amount of a composition comprising, in admixture:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient, which is budesonide;
characterized in that the patient is instructed to inhale the composition on demand, as determined by the patient based on the patient's symptoms, as a treatment and a preventive measure, when the patient experiences an increase in asthma symptoms.

Claim 14 (Currently Amended): The method according to claim 13, wherein the molar ratio of (a) to (b) calculated as formoterol to budesonide is from 1:1 to 1:100, ~~preferably from 1:1 to 1:70.~~

Claim 15 (Currently amended): The method according to claim 13 ~~or 14~~, wherein the first active ingredient is formoterol fumarate dihydrate.

Claim 16 (Currently Amended): The method according to ~~any of claims claim 13 to 15, previous claim,~~ wherein the first active ingredient is the R,R enantiomer of formoterol.

Claim 17 (Currently Amended): The method according to ~~any of claims~~ claim 13 to 16, wherein a unit dose of formoterol lies in the range of from 1 µg to 48 µg, ~~preferably between 3 µg to 12 µg~~, calculated as formoterol fumarate dihydrate.

Claim 18 (Currently Amended): The method according to ~~any of claims~~ claim 13 to 17, wherein the daily dose of formoterol, including maintenance therapy, lies in the range of from 1 µg to 100 µg, ~~preferably from 2 µg to 60 µg~~, calculated as formoterol fumarate dihydrate.

Claim 19 (Currently Amended): The method according to ~~any of claims~~ claim 13 to 18, wherein the second active ingredient is the 22R epimer of budesonide.

Claim 20 (Currently Amended): The method according to ~~any of claims~~ claim 13 to 19, wherein a unit dose of budesonide lies in the range of from 20 µg to 1600 µg, ~~preferably between 50 µg to 400 µg~~.

Claim 21 (Currently Amended): The method according to ~~any of claims~~ claim 13 to 20, wherein the daily dose of budesonide, including maintenance therapy, lies in the range of from 20 µg to 4800 µg, ~~preferably from 30 µg to 3200 µg~~.

Claim 22 (Currently Amended): The method according to ~~any of claims~~ claim 13 to 21, wherein the particle size of the active ingredients (a) and (b) is less than 10 µm.

Claim 23 (Currently Amended): The method according to ~~any of claims~~ claim 13 to 22, wherein the composition additionally comprises one or more pharmaceutically acceptable additives, diluents or carriers.

Claim 24 (Original): The method according to claim 23, wherein the pharmaceutically acceptable additive, diluent or carrier is lactose monohydrate.

Claim 25 (New): The method according to claim 14, wherein the molar ratio of (a) to (b) calculated as formoterol to budesonide is from 1:1 to 1:70.

Claim 26 (New): The method according to claim 17, wherein a unit dose of formoterol lies in the range of from 3 μg to 12 μg , calculated as formoterol fumarate dihydrate.

Claim 27 (New): The method according to claim 18, wherein the daily dose of formoterol, including maintenance therapy, lies in the range of from 2 μg to 60 μg , calculated as formoterol fumarate dihydrate.

Claim 28 (New): The method according to claim 20, wherein a unit dose of budesonide lies in the range of from 50 μg to 400 μg .

Claim 29 (New): The method according to claim 21, wherein the daily dose of budesonide, including maintenance therapy, lies in the range of from 30 μg to 3200 μg .

Claim 30 (New): The method according to claim 13 further comprising instructing the patient to inhale the composition as a rescue medication.

Claim 31 (New): The method according to claim 13 further comprising instructing the patient to take a second composition, comprising a glucocorticosteroid, on a regular basis as a maintenance treatment.

Claim 32 (New): The method according to claim 13 further comprising instructing the patient to use the composition as a complement to maintenance treatment of the patient's asthma.

Claim 33 (New): The method according to claim 13 further comprising instructing the patient to inhale an effective amount of the composition as a preventive measure prior to encountering an asthma triggering event.

Claim 34 (New): The method of claim 33 wherein the asthma triggering event is selected from the group consisting of exposure to cold air, exercise, and exposure to a smoky environment.

Claim 35 (New): A method of prevention and treatment of asthma, which comprises

instructing a patient to inhale an effective amount of a composition comprising, in admixture:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient, which is budesonide;

characterized in that the patient is instructed to inhale the composition on demand, as determined by the patient based on the patient's symptoms, as a complement to maintenance treatment of the patient's asthma.

Claim 36 (New): A method of prevention and treatment of asthma, which comprises instructing a patient to inhale an effective amount of a composition comprising, in admixture:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient, which is budesonide;

characterized in that the patient is instructed to inhale the composition on demand, as determined by the patient, when the patient is expecting to encounter an asthma trigger, as a preventative measure.

Claim 37 (New): The method of claim 13 further comprising instructing the patient to inhale the composition daily as a maintenance treatment.

Claim 38 (New): The method of claim 13 further comprising instructing the patient to use the composition as a complement to maintenance treatment of the patient's asthma.

Claim 39 (New): The method of claim 35 further comprising instructing the patient to inhale the composition daily as the maintenance treatment.

Claim 40 (New): The method of claim 36 further comprising instructing the patient to inhale the composition on demand as a rescue medicine.

Claim 41 (New): The method of claim 36 further comprising instructing the patient to inhale the composition daily as a maintenance treatment.

Claim 42 (New): A method of prevention and treatment of asthma, which comprises instructing a patient to inhale an effective amount of a composition comprising, in admixture:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient, which is budesonide;

characterized in that the patient is instructed to take a maintenance dose of the composition, and, if the patient experiences asthma symptoms, to inhale additional doses as needed to improve control and provide acute relief.